13 results about "Intraocular Injections" patented technology

Provided is an intraocular injection assembly, comprising an injection needle base and an injection needle head. The injection needle base is internally provided with a plurality of first auxiliary channels, each extending in an axial direction of the injection needle base, which are in sequential communication with each other, and in a direction from a first end to a second end of the injection needle base, the diameters of the plurality of first auxiliary channels sequentially decrease, and the plurality of first auxiliary channels cooperate to form a first injection channel. The injection needle head is internally provided with at least two second auxiliary channels, each extending in an axial direction of the injection needle head, which are in sequential communication with each other, and in a direction from a first end to a second end of the injection needle head, the diameters of the second auxiliary channels sequentially decrease, and the second auxiliary channels cooperate to form a second injection channel. The injection needle head is connected to the second end of the injection needle base, and the first end of the injection needle base can be connected to an outlet of an external syringe, such that the second injection channel is in communication with the external syringe by means of the first injection channel.

The utility model provides an intraocular injection assembly, and relates to the technical field of medical instruments. The intraocular injection assembly comprises an injection needle seat and an injection needle; a plurality of first auxiliary channels which extend in the axial direction of the injection needle base and are sequentially communicated with one another are arranged in the injection needle base, the diameters of the first auxiliary channels are sequentially reduced in the direction from the first end to the second end of the injection needle base, and the first auxiliary channels are matched to form a first injection channel; at least two second auxiliary channels which extend in the axial direction of the injection needle and are sequentially communicated with one another are arranged in the injection needle, the diameters of the second auxiliary channels are sequentially reduced in the direction from the first end to the second end of the injection needle, and the second auxiliary channels are matched to form a second injection channel; the injection needle is connected to the second end of the injection needle base, and the first end of the injection needle base can be connected to an outlet of an external injector so that the second injection channel can be communicated with the external injector through the first injection channel. According to the intraocular injection assembly, the flowing speed is increased, the injection time is shortened, and the infection risk is reduced.

This utility model relates to the field of restraint technology for laboratory monkeys, specifically to a supine restraint device for eye experiments on laboratory monkeys. The device includes: a support plate with a groove, and a rotating seat extending along the groove; a head support component connected to the rotating seat and tiltable at a predetermined angle relative to the rotating seat; and a back support component connected to the groove and movable relative to the support plate along the length of the groove to a predetermined position. This restraint device supports the laboratory monkey in a supine position through three support points: head, back, and buttocks. This ensures the monkey is in a neutral position, preventing lateral tilting and facilitating intraocular injection, while minimizing restraint. This allows for observation of conditioned reflexes in monkeys under deep anesthesia and prevents accidental death.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The invention belongs to the technical field of medicines, and particularly relates to application of IR808 in preparation of a medicine for treating eye bacterial infection diseases. According to the invention, IR808 is taken as a photosensitizer, laser irradiation is combined, and singlet oxygen generated by IR808 is utilized to play an antibacterial role. The developed eye drops, intraocular injections, sustained-release nanoparticles and gel preparations are designed aiming at the eye environment, and have good biocompatibility and stability. The treatment scheme in an animal model proves that pathogens including drug-resistant bacteria can be efficiently killed at low concentration, intraocular tissue damage caused by infection can be effectively relieved, and observable toxicity to intraocular cells and the whole body of an experimental animal is not shown. The invention provides a novel effective method for treating bacterial infection of eyes, especially for solving the drug resistance of antibiotics and improving the treatment safety.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

Methods and pharmaceutical compositions for treating ocular disease are disclosed, including ocular disease involving ocular vascular permeability or ocular inflammation. In various aspects and embodiments, the invention comprises administering about 1 μg to about 1 mg of collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to about once every two years. In various embodiments, the methods and compositions provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.

This invention provides the use of spermidine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating autoimmune uveitis. The medicament is formulated as an oral or intraocular injection. The medicament is used to rebuild ocular immune tolerance by promoting autophagy flux activation and downregulating the expression of LCN2 protein in local tissues, inhibiting the differentiation of CD4+ T cells into Th17 cells and promoting their differentiation into Treg cells. Spermine exhibits significant efficacy and high safety in treating autoimmune uveitis.

The present invention relates to the field of stabilized biopolymer compositions, and in particular to stabilized biopolymer compositions comprising a liquid mixture, particularly an aqueous solution, of at least one biopolymer component and at least one stabilizing surfactant. More specifically, the present invention relates to stabilized biopolymer compositions comprising an ethylene oxide / butylene oxide block copolymer, which can impart superior properties to the biopolymer composition compared to currently known formulations, particularly with respect to aggregation tendency, hemolytic activity, and solubility. The present invention further relates to the block copolymer, a method for preparing the stabilized composition, and the use of the block copolymer to stabilize an aqueous composition of the biopolymer. The present invention further relates to the stabilized composition for use in medicine, particularly for diagnostic and / or therapeutic applications. The present invention further relates to an essentially dry biopolymer composition comprising the biopolymer and the block copolymer, and a method for preparing the essentially dry composition. The present invention further relates to the essentially dry biopolymer composition for use in medicine, particularly for diagnostic and / or therapeutic applications. The compositions may be formulated as pharmaceutical compositions that can be delivered via a suitable route of administration, such as oral, rectal, transmucosal, topical, ophthalmic, otorhinological, or enteral administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injection, and, in some cases, epidural, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injection.

The invention discloses application of antisense nucleotide for inhibiting NEAT1 in a targeted parasite assembly domain to treatment, improvement or prevention of fundus neovascularization, and belongs to the technical field of biological medicine. The invention finds that NEAT1 and downstream pro-angiogenesis factors CYR61 and FGF2 are obviously up-regulated in wet age-related macular degeneration patients and CNV model mice. According to the invention, the NEAT1 in the retina and the choroid is efficiently inhibited by designing ASO of a specific targeting lncRNA NEAT1 functional key domain, namely, a para-plaque assembly domain. Furthermore, ASO of a targeted mouse Neat1 homologous domain is subjected to intraocular injection, and laser-induced CNV focus formation can be remarkably inhibited in vivo. The invention provides a candidate drug for treating fundus neovascularization, which is independent of the traditional VEGF pathway and novel in action mechanism, and provides a new solution for patients who are insensitive to anti-VEGF therapy or need long-acting treatment.

The disclosure relates to inflammatory condition-specific drug-releasing hydrogels for ocular injection and uses thereof. According to a hydrogel according to an aspect, the release of a drug may be controlled selectively for an inflammatory condition, and direct intraocular injection is possible.

This invention discloses a fixation table for zebrafish microsurgery, belonging to the field of biological experimental instrument technology. The fixation table includes a culture device, a silicone fish sleeve, a compression ring, a universal ball joint mechanism, and a connector. The silicone fish sleeve is a hollow, flexible, contoured sleeve with a compression ring at its expanded end. By rotating the compression ring, the flexible wall of the silicone fish sleeve contracts inwards uniformly, wrapping and fixing the zebrafish's body in a non-invasive manner. The locking end of the fish sleeve exposes the fish's head, facilitating surgical operations. The universal ball joint mechanism connects to the compression ring via the connector, enabling rapid adjustment and locking of the fish body at any angle in three-dimensional space, meeting the needs of various surgical positions such as upright, inverted, and lateral placement. This invention solves the problems of easy slippage, uneven pressure, difficulty in body position adjustment, and cumbersome operation in existing zebrafish fixation methods, and is suitable for various delicate microsurgeries such as mandibular bone injuries, intraocular injections, and craniotomy.

The present application belongs to the field of pharmaceutical preparations, and relates to a series of multivalent TAT delivery carriers and complexes thereof constructed by using multi-arm polyethylene glycol and TAT or TAT derivatives. The multivalent TAT delivery carrier has an octopus-like flexible structure, can self-assemble with biological macromolecules, especially genes, to form a non-covalent complex, has a strong ability to carry, deliver and penetrate ocular tissues, does not produce ocular tissue toxicity, can realize effective delivery of biological macromolecule drugs into the eye or the fundus through a non-invasive route, and increases the uptake of ocular tissues to the biological macromolecule drugs. The complex formed by self-assembly of the multivalent TAT delivery carrier and biological macromolecules is used for eye drop administration, can replace the poor patient compliance of intraocular injection administration, and enhances the convenience and safety of treating intraocular and fundus diseases.